Navigation Links
Interim Safety Data Favorable for Vical's Phase 2 Trial of DNA Vaccine Against CMV
Date:10/17/2007

come infected during pregnancy.

CMV infection affects 30 to 60 percent of the patients undergoing various transplant procedures, causing transplant rejection, serious illness and even death if untreated. Expensive antiviral drug therapy is used to control the disease, but does not eliminate the infection. Congenital CMV infection affects one out of every hundred infants, and causes severe consequences in about 3,600 infants and death in about 400 each year in the United States.

There is no approved vaccine against CMV. Vaccine approaches that result in predominantly antibody responses to CMV have not proven highly effective in transplant patients. Vaccine approaches using live, attenuated viruses can induce both antibody and cellular immune responses, but pose a potential safety concern, particularly for immunocompromised patients, of causing the disease they are intended to prevent. Vical's novel DNA vaccine approach is designed to induce both antibody and cellular immune responses against specific features of the CMV virus without the risk of causing CMV disease. Vical's vaccine has received orphan drug designation for hematopoietic stem cell transplant and solid organ transplant patients.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to c
'/>"/>

SOURCE Vical Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)...  BioPhotas, Inc., an FDA registered medical device manufacturer ... to treat skin, muscle and joint conditions, today announced ... to provide BioPhotas, flagship product, the Celluma, ... Commenting on the alliance, Patrick ... Celluma at the Warrior Hope and Care Center had ...
(Date:3/5/2015)... -- CANTEL MEDICAL CORP. (NYSE: CMN ) will ... 2015 on Thursday, March 12 before the market opens, and ... AM ET. To participate in the conference ... the beginning of the call. If you are unable to ... from Thursday, March 12, 2015 through midnight on May 12, ...
(Date:3/5/2015)... , March 5, 2015   ndd Medical ... testing (PFT) that employs precise ultrasound technology, announced that ... event held by the San Antonio Pulmonary Fibrosis Support ... (ILD) or pulmonary fibrosis (PF), as well as those ... a footprint of a mere 12 square inches, EasyOne ...
Breaking Medicine Technology:BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 3Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 2ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 3
... 22, 2010 Pfizer Inc (NYSE: PFE ... to both the United States Food and Drug Administration ... the use of Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine ... and older for the prevention of pneumococcal disease caused ...
... Dec. 22, 2010 Haemonetics Corporation (NYSE: ... Chief Executive Officer, will present at the J.P. Morgan ... 2011 at 1:30 pm Pacific time.  The ... at http://jpmorgan.metameetings.com/webcasts/healthcare11/directlink?ticker=HAE .  The webcast ...
Cached Medicine Technology:Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older 2Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older 3Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older 4Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older 5
(Date:3/6/2015)... (PRWEB) March 06, 2015 “ Pokemini ” ... which features the latest and coolest mobile applications on the ... expert and host of NewsWatch, conducted the app review and ... game. , Over the last couple of years, mobile ... to the game. For example, Candy Crush allows users to ...
(Date:3/6/2015)... Ticket Down is a reputable source for ... the Moda Center. After being away from the touring ... no signs of letting up on his “Garth Brooks World ... wife, Trisha Yearwood, to venues around the United States. The ... acclaimed tour to the Moda Center in Portland, OR. The ...
(Date:3/6/2015)... As the Muscular Dystrophy Association continues to enhance its ... two new Scientific Program Officers, Amanda Haidet-Phillips, Ph.D and ... Pavlath, Ph.D, who joined MDA late last year as ... will lead MDA as it accelerates new front-line discovery ... of neuromuscular and motor neuron diseases. , ...
(Date:3/6/2015)... CA (PRWEB) March 06, 2015 US ... of three Maryland camps – two non-contact specialty camps ... be run by Perfect Performance Training, located at Bowie ... focus on developing position specific skills, speed and strength ... hosted at Salisbury University with Marvin Graves, former quarterback ...
(Date:3/6/2015)... California (PRWEB) March 06, 2015 Johnson ... million jury verdict on March 5, 2015 in Superior ... According to court documents, a jury of 12 awarded ... suffered from being implanted with an Ethicon TVT Abbrevo ... nine men and three women also awarded $5 million ...
Breaking Medicine News(10 mins):Health News:A Kawaii Social Game was Featured on NewsWatch Television on February 26, 2015 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3
... for first time treatment of advanced lung cancer in ... randomised study on lung cancer patients led by Dr.Alan ... at Vanderbilt-Ingram Cancer Center. ,Nearly 900 patients ... the trial. None of them had received any previous ...
... the world today, Britain had to face the embarrassment of ... week. //In a recent report by CABE it was brought ... population can be declared obese and overweight. ,The ... headquarters in London works towards improving people's quality of life ...
... to investigate a botched cataract surgery camp at the Guwahati ... ,Health Minister Himanta Biswa Sarma said the enquiry would be ... and was expected to submit the report in three months. ... hence instituted a judicial probe to fix responsibility for the ...
... Virus type C (GBV-C) protects against HIV infection is now ... Iowa// City Health Care System and the University of Iowa ... growing in cell models. ,The team found that ... NS5A greatly slows down HIV from replicating in cells grown ...
... Hospital have developed a revolutionary treatment for dementia.// ... Research Centre George Razay merely merely draining fluid from ... 5000 Tasmanians are affected by dementia and the figure ... ,20 patients, equal number of men and women ...
... In order to restrict the use animals for the ... new techniques are being developed by researchers at the ... as a financial grant. ,Gauging the carcinogenic effects ... which further necessitates the use of live animals to ...
Cached Medicine News:Health News:Judicial Probe Ordered for Botched Eye Surgery Camp 2Health News:Study IDs Protein That Inhibits HIV From Growing In Cell Cultures 2Health News:Study IDs Protein That Inhibits HIV From Growing In Cell Cultures 3Health News:Grant Encourages Drug Testing Sans Animals 2
The cordless Simon Dermatome with rechargeable battery is used to harvest split-thickness skin grafts and for debridement....
Forceps with round handle, straight...
Castroviejo microscopic needle holder...
Microscopic scissors, curved...
Medicine Products: